A. Planting

发表

Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.

M. J. van den Bent, J. Verweij, J. Schellens, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors

P. Sonneveld, P. Sonneveld, J. Verweij, 2004, Cancer Chemotherapy and Pharmacology.

Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2004, European Journal of Cancer.

Preoperative chemoradiation with capecitabine in locally advanced rectal cancer.

J. Nuyttens, J. D. de Wilt, C. Verhoef, 2008, The Netherlands journal of medicine.

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.

J. Verweij, A. Sparreboom, R. Mathijssen, 2006, The oncologist.

Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin.

J. Verweij, A. Sparreboom, P. de Bruijn, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abnormal liver metabolism in cancer patients detected by 31P MR spectroscopy

P. Dagnelie, P. Sijens, A. Planting, 1999, NMR in biomedicine.

A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial.

O. Dalesio, P. Drings, A. Kirkpatrick, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM 486 A in Combination with 5-Fluorouracil / Leucovorin in Metastatic Colorectal Cancer

J. Ledermann, J. Verweij, J. Bridgewater, 2004 .

Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/ Leucovorin in Metastatic Colorectal Cancer

J. Ledermann, J. Verweij, L. van Zuylen, 2004, Clinical Cancer Research.

Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck.

J. Verweij, P. D. De Mulder, A. de Graeff, 1997, European journal of cancer.

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.

H. Hansen, J. Verweij, H. Rosing, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.

J. Verweij, J. Schellens, D. V. Von Hoff, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.

J. Verweij, J. Schellens, D. V. Von Hoff, 1998, European journal of cancer.

A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer

M. J. van den Bent, J. Verweij, J. Schellens, 1997, Cancer Chemotherapy and Pharmacology.

Phase I study of intravenous fosquidone (GR63178A-NSC D611615) using a three times a week schedule.

J. Verweij, G. Stoter, M. V. D. Van Der Burg, 1992, Clinics in oncology.

The potential of statins as part of anti-cancer treatment.

S. Sleijfer, J. Verweij, A. van der Gaast, 2005, European journal of cancer.

Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC Malignant Melanoma Cooperative Group

E. Bröcker, R. MacKie, U. Kleeberg, 1992, Melanoma research.

Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.

J. Verweij, P. D. De Mulder, W. Oster, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary

J. Nuytens, J. Wilt, A. Planting, 2007 .

Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.

J. Verweij, H. Gelderblom, A. Sparreboom, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radioimmunodetection and Radioimmunotherapy in Myosarcoma

J. Verweij, G. Stoter, A. Planting, 1989 .

An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors.

J. Verweij, H. Burger, K. Hayashi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.

M. J. van den Bent, J. Verweij, J. Schellens, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.

J. Verweij, C. Punt, A. Sparreboom, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.

S. Clarke, J. Verweij, I. Judson, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule

M. Bent, P. Hilkens, J. Moll, 1994, European journal of neurology.

Nursing care adaptations during clinical trials with weekly high‐dose cisplatin: evaluation of a process plan

J. Verweij, G. Stoter, A. Planting, 1993 .

Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma.

J. Verweij, R. de Wit, G. Stoter, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors.

J. Verweij, G. Stoter, M. V. D. Van Der Burg, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration.

M. J. van den Bent, W. van Putten, C. Vecht, 1995, European journal of cancer.

Weekly high-dose cisplatin in malignant pleural mesothelioma.

J. Verweij, J. Schellens, G. Stoter, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Asbestos bodies and fibers in lung tissue

J. Verweij, G. Stoter, M. V. D. Van Der Burg, 1974, Environmental Health Perspectives.

A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours

J. Verweij, G. Stoter, A. Planting, 1992, Journal of Cancer Research and Clinical Oncology.

Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.

J. Verweij, G. Stoter, L. Pronk, 1994, European journal of cancer.

Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.

J. Verweij, G. Stoter, A. Planting, 1993, European journal of cancer.

Phase II study of oral miltefosine in patients with squamous cell head and neck cancer.

J. Verweij, J. Armand, G. Stoter, 1993, European journal of cancer.

O. Dalesio, P. Drings, A. Kirkpatrick, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.

L. Gras, J. Wanders, J. Verweij, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and side effects of two chemotherapy regimens with cisplatin plus fluorouracil in advanced squamous cell carcinoma of the head and neck.

J. Verweij, P. Schmitz, G. Stoter, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer.

M. J. van den Bent, J. Verweij, G. Stoter, 1996, British Journal of Cancer.

Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.

J. Verweij, C. Punt, A. Sparreboom, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.

J. Verweij, J. Schellens, W. Loos, 1994, Journal of the National Cancer Institute.

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

J. Verweij, P. Workman, I. Judson, 2009, Molecular Cancer Therapeutics.

Weekly scheduling of cisplatin: feasibility, efficacy and perspective

A. Planting, 1996 .

Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.

W. Hop, J. Verweij, A. van der Gaast, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma.

J. Verweij, J. Schellens, C. Vecht, 1996, European journal of cancer.

Short report: Phase II study of cisplatin plus 24-hour infusion of ifosfamide in advanced malignant melanoma

J. Verweij, G. Stoter, A. Planting, 1990 .

Phase II study of cisplatin plus 24-hour infusion of ifosfamide in advanced malignant melanoma.

J. Verweij, A. van der Gaast, G. Stoter, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.

J Verweij, J. Verweij, A. Sparreboom, 1999, Anti-cancer drugs.

A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan

E. Wiemer, J. Verweij, A. Sparreboom, 2010, Clinical Cancer Research.

Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.

J. Verweij, A. Sparreboom, R. Mathijssen, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors

J. Verweij, D. Noe, P. Schöffski, 2005, Cancer Chemotherapy and Pharmacology.

Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies

C. Bucana, J. Verweij, I. Fidler, 2005, Clinical Cancer Research.

The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary

J. Verweij, S. Henzen‐Logmans, G. Stoter, 1996, Journal of Cancer Research and Clinical Oncology.

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.

B. Reigner, J. Verweij, J. Schellens, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The "Liver-First Approach" for Patients with Locally Advanced Rectal Cancer and Synchronous Liver Metastases

A. Eggermont, J. Nuyttens, J. D. de Wilt, 2009, Diseases of the colon and rectum.

Evidence-base guideline on management of colorectal liver metastases in the Netherlands.

P. Bossuyt, J. Stoker, M. V. van Leeuwen, 2007, The Netherlands journal of medicine.

A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)

J. Verweij, J. Schellens, D. V. Von Hoff, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes

J. Verweij, J. Schellens, W. Loos, 1996, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.

J. Wanders, J. Verweij, L. Denis, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

The polyamine synthesis inhibitor SAM486A in combination with 5-FU/LV in metastatic colorectal cancer (MCC): results of a phase I and pharmacokinetic study

J. Ledermann, J. Verweij, J. Bridgewater, 2000 .

Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.

J. Verweij, J. Schellens, G. Stoter, 1999, Anti-cancer drugs.

Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial.

B. Baron, A. Planting, J. Wils, 2002, European journal of cancer.

[Myocardial ischaemia as a result of treatment with capecitabine].

A. Liem, A. Planting, H. V. van Halteren, 2007, Nederlands tijdschrift voor geneeskunde.

Phase II study of carboplatin and etoposide as a first line regimen in patients with metastatic breast cancer.

M. Bontenbal, A. van der Gaast, A. Planting, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of oral administration of etoposide for patients with well- and moderately-differentiated adenocarcinomas of unknown primary site.

J. Verweij, S. Henzen‐Logmans, A. van der Gaast, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Effects of methimazole on the elimination of irinotecan

E. Wiemer, J. Verweij, J. Schellens, 2010, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and Pharmacokinetic Study of Brostallicin ( PNU-166196 ) , a New DNA Minor-Groove Binder , Administered Intravenously Every 3 Weeks to Adult Patients with Metastatic Cancer 1

J. Verweij, A. Sparreboom, F. Fiorentini, 2003 .

Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.

H. Rosing, J. Beijnen, J. Schellens, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of high dose ifosfamide in metastatic colorectal cancer.

J. Verweij, G. Stoter, A. Hoff, 1989, European journal of cancer & clinical oncology.

Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung

O. Dalesio, J. Smyth, A. Kirkpatrick, 1989 .

Phase I and Pharmacokinetic Study of the Dolastatin 10 Analogue TZT-1027, Given on Days 1 and 8 of a 3-Week Cycle in Patients with Advanced Solid Tumors

J. Wanders, J. Verweij, M. D. de Jonge, 2005, Clinical Cancer Research.

A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan

E. Wiemer, J. Verweij, A. Sparreboom, 2010, Clinical Cancer Research.

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

cis-Platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group.

O. Dalesio, A. Planting, N. Duez, 1985, European journal of cancer & clinical oncology.

Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained.

J. Verweij, P. D. De Mulder, P. Schmitz, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.

R. Obach, J. Verweij, C. Twelves, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.